logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10287299 B1

PDFFull Text
Date of Patent:
May. 14, 2019

Filed:

Jun. 07, 2016

Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity

Applicant:

Ucb Biopharma Sprl, Brussels, BE;

Inventors:

Gareth Neil Brace, Abingdon, GB;

Prafulkumar Tulshibhai Chovatia, Abingdon, GB;

Gregory Foulkes, Abingdon, GB;

James Andrew Johnson, Slough, GB;

Severine Danielle Jones, Abingdon, GB;

Boris Kroeplien, Slough, GB;

Fabien Claude Lecomte, Slough, GB;

Pui Leng Loke, Abingdon, GB;

Martin Alexander Lowe, Slough, GB;

Ajay Mandal, Abingdon, GB;

Timothy John Norman, Slough, GB;

Christopher Francis Palmer, Abingdon, GB;

Yolanda Pérez-Fuertes, Abingdon, GB;

John Robert Porter, Slough, GB;

Donald Smyth, Abingdon, GB;

Giancarlo Trani, Abingdon, GB;

Muhammed Uddin, Abingdon, GB;

Zhaoning Zhu, Slough, GB;

Assignee:

UCB Biopharma SPRL, Brussels, BE;

Attorney:

McDonnell Boehnen Hulbert & Berghoff LLP

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/5365 (2006.01); C07D 265/36 (2006.01); C07D 498/04 (2006.01); C07D 401/06 (2006.01); C07D 413/06 (2006.01); A61P 27/02 (2006.01); A61P 3/00 (2006.01); A61P 9/00 (2006.01); A61P 23/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61K 31/423 (2006.01); A61K 31/4375 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4725 (2006.01); A61K 31/473 (2006.01); A61K 31/538 (2006.01); A61K 31/5383 (2006.01); A61K 31/55 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 498/04 (2013.01); A61K 31/423 (2013.01); A61K 31/4375 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/473 (2013.01); A61K 31/4725 (2013.01); A61K 31/538 (2013.01); A61K 31/5383 (2013.01); A61K 31/55 (2013.01); A61P 3/00 (2018.01); A61P 9/00 (2018.01); A61P 23/00 (2018.01); A61P 25/00 (2018.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); C07D 401/06 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01);
Abstract

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Find Patent Forward Citations

Loading…